Syros Pharmaceuticals (SYRS) – Analyst Ratings
-
"There is Upside to Market Potential and Our Outlook" of SY-1425 - Brookline Capital Markets Bullish on Syros Pharmaceuticals (SYRS) with Buy Rating and $19 Price Target
-
Oppenheimer Reiterates Outperform Rating, $9 Price Target on Syros Pharmaceuticals (SYRS), "Investors Can Look Forward to Multiple Catalysts"
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SYRS Stock Lookup